FDA-Approved Oligonucleotide Therapies in 2017

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1069-1075

  Stein, Cy A ^a   Castanotto, Daniela ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

aptamer; Defitelio; Eteplirsen; Kynamro; Macugen; oligonucleotide; phosphorothioate; Spinraza; therapeutics; Vitravene

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; DEFIBROTIDE; DYSTROPHIN; ETEPLIRSEN; FOMIVIRSEN; IMMEDIATE EARLY PROTEIN; MESSENGER RNA; MIPOMERSEN; NUSINERSEN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; SMALL INTERFERING RNA; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; APTAMER; MORPHOLINO OLIGONUCLEOTIDE; NUCLEOTIDE; OLIGONUCLEOTIDE; POLYDEOXYRIBONUCLEOTIDE;

AGE RELATED MACULAR DEGENERATION; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BLEEDING; CONSTIPATION; CYTOMEGALOVIRUS RETINITIS; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ENDOPHTHALMITIS; ENZYME INHIBITION; EXON SKIPPING; EYE INJURY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LENS DISEASE; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MAINTENANCE DRUG DOSE; NEPHROTOXICITY; OLIGONUCLEOTIDE THERAPY; RESPIRATORY TRACT INFECTION; REVIEW; SIX MINUTE WALK TEST; SPINAL MUSCULAR ATROPHY; STOP CODON; SURVIVAL RATE; THROMBOCYTOPENIA; VIRUS REPLICATION; VISUAL ACUITY; CLINICAL TRIAL (TOPIC); GENETICS; HYPERCHOLESTEROLEMIA; MACULAR DEGENERATION; PATHOLOGY; VIROLOGY;

APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS RETINITIS; DRUG APPROVAL; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; MACULAR DEGENERATION; MORPHOLINOS; MUSCULAR ATROPHY, SPINAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; POLYDEOXYRIBONUCLEOTIDES; THIONUCLEOTIDES;

EID: 85018768469     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.023     Document Type: Review

References (61)

1. 1 Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133 (2002), 467–474.
2. 2 Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990), 505–510.
3. 3 Eaton, B.E., The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Curr. Opin. Chem. Biol. 1 (1997), 10–16.
4. 4 Ng, E.W., Shima, D.T., Calias, P., Cunningham, E.T. Jr., Guyer, D.R., Adamis, A.P., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006), 123–132.
5. 5 Ruckman, J., Green, L.S., Beeson, J., Waugh, S., Gillette, W.L., Henninger, D.D., Claesson-Welsh, L., Janjić, N., 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273 (1998), 20556–20567.
6. 6 Jellinek, D., Green, L.S., Bell, C., Janjić, N., Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33 (1994), 10450–10456.
7. 7 Gragoudas, E.S., Adamis, A.P., Cunningham, E.T. Jr., Feinsod, M., Guyer, D.R., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004), 2805–2816.
8. 8 D'Amico, D.J., VEGF inhibition study in ocular neovascularization (VISION): Second year efficacy data. Invest. Ophthalmol. Vis. Sci., 46, 2005, 2309.
9. 9 http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/modernmedicine/modern-medicine-news/valeant-acquires-eyetech.
10. 10 Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 998–1006.
11. 11 Besseling, J., Sjouke, B., Kastelein, J.J.P., Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis 241 (2015), 597–606.
12. 12 Crooke, R.M., Graham, M.J., Lemonidis, K.M., Whipple, C.P., Koo, S., Perera, R.J., An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46 (2005), 872–884.
13. 13 De Mesmaeker, A., Haener, R., Martin, P., Moser, H.E., Antisense oligonucleotides. Acc. Chem. Res. 28 (1995), 366–374.
14. 14 Davidson, N.O., Shelness, G.S., APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20 (2000), 169–193.
15. 15 Mahley, R. Biochemistry and Physiology of Lipid and Lipoprotein Metabolism. In Principles and Practice of Endocrinology and Metabolism, Third Edition, K.L. Becker, ed. (Lippincott Williams and Wilkins).
16. 16 McGowan, M.P., Tardif, J.C., Ceska, R., Burgess, L.J., Soran, H., Gouni-Berthold, I., Wagener, G., Chasan-Taber, S., Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE, 7, 2012, e49006.
17. 17 Stein, E.A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J.M., Chin, W., Tribble, D.L., McGowan, M., Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126 (2012), 2283–2292.
18. 18 Thomas, G.S., Cromwell, W.C., Ali, S., Chin, W., Flaim, J.D., Davidson, M., Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62 (2013), 2178–2184.
19. 19 Excerpted from: Stein, C.A. (2016). Eteplirsen approved for Duchenne muscular dystrophy: The FDA faces a difficult choice. Mol. Ther. 24, 1884–1885.
20. 20 Robinson-Hamm, J.N., Gersbach, C.A., Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum. Genet. 135 (2016), 1029–1040.
21. 21 Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Kota, J., et al., Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74 (2013), 637–647.
22. 22 van Deutekom, J.C., de Kimpe, S.J., Campion, G.V., Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy. Drug Discov. Today Ther. Strateg. 10 (2013), e149–e156.
23. 23 Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378 (2011), 595–605.
24. 24 Mendell, J.R., Goemans, N., Lowes, L.P., Alfano, L.N., Berry, K., Shao, J., Kaye, E.M., Mercuri, E., Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79 (2016), 257–271.
25. 25 Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8 (2009), 918–928.
26. 26 Aartsma-Rus, A., Ferlini, A., Goemans, N., Pasmooij, A.M., Wells, D.J., Bushby, K., Vroom, E., Balabanov, P., Translational and regulatory challenges for exon skipping therapies. Hum. Gene Ther. 25 (2014), 885–892.
27. 27 Carrol. J. UPDATED: The FDA decides that it can't decide yet on Sarepta's eteplirsen. http://www.fiercebiotech.com/fda-decides-it-can-t-decide-yet-sarepta-s-eteplirsen.
28. 28 Feuerstein, A. Sarepta, FDA compromise on plan to secure Duchenne drug approval. The Street, June 7, 2016. https://www.thestreet.com/story/13598536/1/sarepta-fda-compromise-on-plan-to-secure-duchenne-drug-approval.html.
29. 29 Editorial. Where's the drug, FDA? The Wall Street Journal, July 5, 2016. http://www.wsj.com/articles/wheres-the-drug-fda-1467413266.
30. 30 Harper, M. Approving a muscular dystrophy drug ignites a civil war at the FDA. Forbes, September 20, 2016. https://www.forbes.com/sites/matthewherper/2016/09/20/approving-a-muscular-dystrophy-drug-ignites-civil-war-at-the-fda/.
31. 31 Excerpted from: Stein, C., Castanotto, D., Krishnan, A., and Nikolaenko, L. (2016). Defibrotide (Defitelio): A new addition to the stockpile of Food and Drug Administration-approved oligonucleotide drugs. Mol. Ther. Nucleic Acids 5, e346.
32. 32 Pescador, R., Capuzzi, L., Mantovani, M., Fulgenzi, A., Ferrero, M.E., Defibrotide: properties and clinical use of an old/new drug. Vascul. Pharmacol. 59 (2013), 1–10.
33. 33 Benimetskaya, L., Wu, S., Voskresenskiy, A.M., Echart, C., Zhou, J.F., Shin, J., Iacobelli, M., Richardson, P., Ayyanar, K., Stein, C.A., Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 112 (2008), 4343–4352.
34. 34 Valla, D.C., Cazals-Hatem, D., Sinusoidal obstruction syndrome. Clin. Res. Hepatol. Gastroenterol. 40 (2016), 378–385.
35. 35 Dalle, J.H., Giralt, S.A., Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol. Blood Marrow Transplant. 22 (2016), 400–409.
36. 36 Fan, C.Q., Crawford, J.M., Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J. Clin. Exp. Hepatol. 4 (2014), 332–346.
37. 37 DeLeve, L.D., Ito, Y., Bethea, N.W., McCuskey, M.K., Wang, X., McCuskey, R.S., Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2003), G1045–G1052.
38. 38 DeLeve, L.D., Shulman, H.M., McDonald, G.B., Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 22 (2002), 27–42.
39. 39 Dignan, F.L., Wynn, R.F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., Veys, P., Potter, M.N. Haemato-oncology Task Force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br. J. Haematol. 163 (2013), 444–457.
40. 40 Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 50 (2015), 781–789.
41. 41 Richardson, P.G., Riches, M.L., Kernan, N.A., Brochstein, J.A., Mineishi, S., Termuhlen, A.M., Arai, S., Grupp, S.A., Guinan, E.C., Martin, P.L., et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127 (2016), 1656–1665.
42. 42 Cheuk, D.K., Chiang, A.K., Ha, S.Y., Chan, G.C., Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst. Rev., 5, 2015, CD009311.
43. 43 Akimoto, T., Hammerman, M.R., Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta. Am. J. Physiol. Cell Physiol. 284 (2003), C371–C377.
44. 44 Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D.B., Biological roles of fibroblast growth factor-2. Endocr. Rev. 18 (1997), 26–45.
45. 45 Basilico, C., Moscatelli, D., The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59 (1992), 115–165.
46. 46 Seghezzi, G., Patel, S., Ren, C.J., Gualandris, A., Pintucci, G., Robbins, E.S., Shapiro, R.L., Galloway, A.C., Rifkin, D.B., Mignatti, P., Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141 (1998), 1659–1673.
47. 47 Jones, L.S., Yazzie, B., Middaugh, C.R., Polyanions and the proteome. Mol. Cell. Proteomics 3 (2004), 746–769.
48. 48 Bashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C.M., Folkman, J., Vlodavsky, I., Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28 (1989), 1737–1743.
49. 49 Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., Klagsbrun, M., Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA 84 (1987), 2292–2296.
50. 50 Baird, A., Ling, N., Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem. Biophys. Res. Commun. 142 (1987), 428–435.
51. 51 Powers, C.J., McLeskey, S.W., Wellstein, A., Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7 (2000), 165–197.
52. 52 Palomo, M., Mir, E., Rovira, M., Escolar, G., Carreras, E., Diaz-Ricart, M., What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood 127 (2016), 1719–1727.
53. 53 Bianchi, G., Barone, D., Lanzarotti, E., Tettamanti, R., Porta, R., Moltrasio, D., Cedro, A., Salvetti, L., Mantovani, M., Prino, G., Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur. J. Pharmacol. 238 (1993), 327–334.
54. 54 Francischetti, I.M., Oliveira, C.J., Ostera, G.R., Yager, S.B., Debierre-Grockiego, F., Carregaro, V., Jaramillo-Gutierrez, G., Hume, J.C., Jiang, L., Moretz, S.E., et al. Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 786–798.
55. 55 Eissner, G., Multhoff, G., Gerbitz, A., Kirchner, S., Bauer, S., Haffner, S., Sondermann, D., Andreesen, R., Holler, E., Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 100 (2002), 334–340.
56. 56 Koehl, G.E., Geissler, E.K., Iacobelli, M., Frei, C., Burger, V., Haffner, S., Holler, E., Andreesen, R., Schlitt, H.J., Eissner, G., Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol. Ther. 6 (2007), 686–690.
57. 57 Echart, C.L., Graziadio, B., Somaini, S., Ferro, L.I., Richardson, P.G., Fareed, J., Iacobelli, M., The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Blood Coagul, Fibrinolysis. 20 (2009), 627–634.
58. 58 Cella, G., Sbarai, A., Mazzaro, G., Motta, G., Carraro, P., Andreozzi, G.M., Hoppensteadt, D.A., Fareed, J., Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin. Appl. Thromb. Hemost. 7 (2001), 225–228.
59. 59 Coccheri, S., Biagi, G., Legnani, C., Bianchini, B., Grauso, F., Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur. J. Clin. Pharmacol. 35 (1988), 151–156.
60. 60 Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M.A., Bennett, C.F., Krainer, A.R., Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24 (2010), 1634–1644.
61. 61 MDA. Spinal muscular atrophy. http://www.mda.org/disease/spinal-muscular-atrophy/types.